Related references
Note: Only part of the references are listed.Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2021)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease
Helene Zephir et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Neurologic Complications in Patients with Inflammatory Bowel Disease: Increasing Relevance in the Era of Biologics
Siddharth Singh et al.
INFLAMMATORY BOWEL DISEASES (2013)
New IBD genetics: common pathways with other diseases
C. W. Lees et al.
GUT (2011)
The comeback kid: TYSABRI now FDA approved for Crohn disease
Karen Honey
JOURNAL OF CLINICAL INVESTIGATION (2008)
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease
CW Thomas et al.
INFLAMMATORY BOWEL DISEASES (2004)
Share Paper
